Latest Breaking News On - Apamistamab improves outcomes - Page 1 : vimarsana.com

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in

United statesSan antonioAvinash desaiInternational blood marrow transplant researchAmerican society for transplantationActimaba national cancer instituteMarrow transplant researchExchange commissionActinium pharmaceuticals incInternational bloodPrnewswire actinium pharmaceuticals incCellular therapyAmerican societyComplete remissionChief medical officerIomabb phase

Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B

Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioAvinash desaiAmerican society for transplantationInternational bloodActinium pharmaceuticals incMarrow transplant researchActinium pharmaceuticalsCellular therapyAmerican societyComplete remissionChief medical officerIomabb phaseApamistamab improves outcomesTargeted myeloablative radiation usingApamistamab prior